GLP-1 receptor agonist
Lixisenatide
Answer
Lixisenatide is authorised or registered in the US, the EU, Canada, Switzerland, Brazil, Serbia, Singapore and Turkey: 8 of the 10 registers read. No trial states a phase. It has 75 registered trials, 6 of them running. Brand names on the FDA label register: Soliqua 100/33.
RegulatorTrial register10 regulators' registers, read 2026-09-03 to 2026-10-03 · ClinicalTrials.gov, read 2026-10-03
Not medical, legal or regulatory advice.
75 trials by status
Trial registerClinicalTrials.gov · read 2026-10-03 · 27 trials have posted results
Trials first submitted per year
Trial registerClinicalTrials.gov first-submitted date, last 10 years · read 2026-10-03. 39 trials carry no first-submitted date (EU CTIS publishes none, or the year is outside this range).
Status by jurisdiction
World map| Where | Status | Register | Read |
|---|---|---|---|
| United States | FDA-approved | FDA, openfda | 2026-10-03 |
| European Union | Authorised | EMA, ema | 2026-10-03 |
| United Kingdom | Not on the register | MHRA, uk-mhra | 2026-09-03 |
| Canada | Authorised | Health Canada, ca-dpd | 2026-10-03 |
| Australia | Status unknown | TGA, au-artg | not read |
| Switzerland | Authorised | Swissmedic, ch-swissmedic | 2026-10-03 |
| Brazil | Registado | ANVISA, br-anvisa | 2026-10-03 |
| Serbia | Authorised | ALIMS, rs-alims | 2026-09-03 |
| Singapore | Registered | HSA, sg-hsa | 2026-09-03 |
| Turkey | Ruhsatli | TITCK, tr-titck | 2026-09-03 |
An EU decision applies in the 30 territories the EU register covers: its member states, and Iceland, Liechtenstein and Norway. A dashed tile has no register read for this peptide.
Side effects
Trial registerCHANGE ALERTS
Get an email when this changes
One email when the status of Lixisenatide changes on the register. You confirm your address first.
REGISTERED TRIALS
Newest 10 of 75 trials
| NCT05220917 | Comparative Effectiveness and Safety of Four Second Line Pharmacological Strategies in Type 2 Diabetes Study running, but no longer enrolling · register updated 2026-08-13 |
|---|---|
| NCT06716424 | A Study to Investigate Safety and Efficacy of iGlarLixi in Adult Patients With Type 2 Diabetes Mellitus completed · register updated 2026-07-10 |
| NCT07307235 | Efficacy and Safety of iGlarLixi Versus Standard of Care in a Real-world Adult China Population With Uncontrolled Type 2 Diabetes currently recruiting participants · register updated 2026-07-07 |
| NCT06671587 | iGlarLixi CGM Study in Chinese T2D Individuals After OADs currently recruiting participants · register updated 2026-03-17 |
| NCT07173712 | Regimen Transition After Short-Term Intensive Insulin Therapy in Type 2 Diabetes not yet recruiting participants · register updated 2026-02-06 |
| NCT03439943 | Study to Evaluate the Effect of Lixisenatide in Patient With Parkinson's Disease completed · register updated 2025-11-28 |
| NCT05413369 | iGlarLixi vs IDegAsp in Chinese Participants After OAD(s) completed · register updated 2025-09-24 |
| NCT07188545 | Using Secondary Data to Evaluate Sex-based Heterogeneity of GLP-1 Agonists and SGLT2 Inhibitors on Cardiovascular-Kidney-Metabolic running, but no longer enrolling · register updated 2025-09-23 |
| NCT07117240 | Evaluation of the Efficacy and Safety of GLP-1 Receptor Agonist Therapy In Steroid-Induced Diabetes enrolling by invitation only · register updated 2025-09-19 |
| NCT05114590 | Effect of Soliqua 100/33 on Time in Range From Continuous Glucose Monitoring in Insulin-naive Patients With Very Uncontrolled Type completed · register updated 2025-09-09 |
WEEKLY
Register Watch, weekly
New trials, approvals and enforcement actions. One email a week.